IRRAS (DB:4Z7) - Cours de l'action, nouvelles et analyse

4Z7 Aperçu des actions

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. Plus de détails

4Z7 analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 84.69% par an

Analyse des risques

Les actions sont très illiquides

A moins d'un an de piste de trésorerie

N'a pas de revenus significatifs ( SEK43M )

Les actionnaires ont été dilués au cours de l'année écoulée

+ 1 plus de risques

IRRAS AB (publ) Concurrents

PULSION Medical Systems

MUN:PUS

€134.4m

Stratec

XTRA:SBS

€334.9m

Eckert & Ziegler

XTRA:EUZ

€897.2m

Drägerwerk KGaA

XTRA:DRW3

€792.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour IRRAS
Historique des cours de bourse
Prix actuel de l'action	US$0.013
Plus haut sur 52 semaines	US$0.041
Plus bas sur 52 semaines	US$0.01
Bêta	0
1Variation sur 1 mois	0%
Variation sur 3 mois	3.15%
Variation sur 1 an	-66.41%
3Variation sur 3 ans	-98.10%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-97.88%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	4Z7	DE Medical Equipment	DE Marché
7D	0%	2.9%	0.8%
1Y	-66.4%	-4.7%	8.6%

Rendement vs Industrie: 4Z7 a sous-performé le secteur German Medical Equipment qui a rapporté -4.7 % au cours de l'année écoulée.

Rendement vs marché: 4Z7 a sous-performé le marché German qui a rapporté 8.6 % au cours de l'année écoulée.

Volatilité des prix

Is 4Z7's price volatile compared to industry and market?
4Z7 volatility
4Z7 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: 4Z7 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de 4Z7 au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2011	47	Will Martin	www.irras.com

IRRAS AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de IRRAS se comparent-ils à sa capitalisation boursière ?
4Z7 statistiques fondamentales
Capitalisation boursière	€167.97m
Bénéfices(TTM)	-€196.40m
Recettes(TTM)	€43.10m

0.0x

Ratio P/S

0.0x

Ratio P/E

Le site 4Z7 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
4Z7 compte de résultat (TTM)
Recettes	SEK 43.10m
Coût des recettes	SEK 44.03m
Marge brute	-SEK 935.00k
Autres dépenses	SEK 195.47m
Les revenus	-SEK 196.40m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

Feb 21, 2024

Résultat par action (EPS)	-0.17
Marge brute	-2.17%
Marge bénéficiaire nette	-455.71%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de 4Z7?

Voir les performances historiques et les comparaisons

4Z7 Aperçu des actions

Récompenses

Analyse des risques

IRRAS AB (publ) Concurrents

MUN:PUS

€134.4m

XTRA:SBS

€334.9m

XTRA:EUZ

€897.2m

XTRA:DRW3

€792.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

IRRAS AB (publ) Résumé des fondamentaux

0.0x

0.0x

Bénéfices et recettes